Drug Profile
Enitociclib - Vincerx Pharma
Alternative Names: BAY-1251152; VIP-152Latest Information Update: 12 Jan 2024
Price :
$50
*
At a glance
- Originator Bayer
- Developer Bayer; Vincerx Pharma
- Class Antineoplastics; Fluorinated hydrocarbons; Organic sulfur compounds; Phenyl ethers; Pyridines; Small molecules
- Mechanism of Action Cyclin dependent kinase 9 inhibitors; Positive transcriptional elongation factor B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Haematological malignancies; Non-Hodgkin's lymphoma
- Phase I Chronic lymphocytic leukaemia; Richter's syndrome; Solid tumours
- Preclinical Multiple myeloma
Most Recent Events
- 12 Jan 2024 Phase I trial in Solid tumours (Late-stage disease, Monotherapy, Second-line therapy or greater) and Non-Hodgkin's lymphoma (Late-stage disease, Monotherapy, Second-line therapy or greater) is still ongoing in USA, Spain and Chile (NCT02635672)
- 07 Jan 2024 Efficacy data from a phase I/II trial in Hematologic malignancies, Non-Hodgkin lymphoma, lymphoma released by Vincerx Pharma
- 09 Dec 2023 Updated pharmacodynamics data from a preclinical trial in Haematological malignancies presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)